Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
Study sponsor: Sol-Gel Technologies, Ltd. · SLGL
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-12-28Actual
Enrollment · participants174Actual
Source updated2024-07-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.